Fig. 4From: Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stromaFlowcharts of steps to determine dose-limiting toxicities in the phase I study. In the phase 1 part study, this is a dose-escalation study using a standard 3 + 3 design. See text for detailsBack to article page